Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISMO vs ACETAMINOPHEN AND HYDROCODONE BITARTRATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isosorbide mononitrate is a nitrate that dilates coronary arteries and peripheral veins. It acts by releasing nitric oxide, which activates guanylate cyclase, increasing c GMP levels, leading to smooth muscle relaxation and vasodilation.
Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.
Prevention of angina pectoris due to coronary artery disease,Off-label: Treatment of acute angina (immediate-release forms)
Moderate to moderately severe pain,Cough suppression (hydrocodone; off-label)
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to minimize nitrate tolerance.
1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Terminal elimination half-life is approximately 5-6 hours. In elderly patients or those with hepatic impairment, half-life may be prolonged (up to 8-10 hours), warranting dose adjustment.
Acetaminophen: 2-3 hours in adults; prolonged in hepatic impairment (up to 5 hours). Hydrocodone: 3.8-4.5 hours (range 3-5 hours) in healthy adults; prolonged in elderly or hepatic/renal impairment. Clinical context: repeated dosing may require extended intervals in renal impairment.
Primarily metabolized in the liver by denitration; minor metabolism via glucuronidation. Metabolites are inactive.
Acetaminophen: primarily via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation; minor CYP2E1 oxidation to NAPQI (toxic metabolite). Hydrocodone: CYP3A4 and CYP2D6; N-demethylation to norhydrocodone; O-demethylation to hydromorphone (CYP2D6).
Primarily renal; 80-90% of the dose is excreted as inactive metabolites (isosorbide mononitrate and isosorbide dinitrate) in urine. Less than 1% is excreted unchanged. Fecal excretion is minimal.
Acetaminophen: primarily renal excretion of conjugated metabolites (glucuronide and sulfate) with approximately 5% excreted unchanged. Hydrocodone: renal excretion as unchanged drug and metabolites (O-demethylated and N-demethylated); total renal excretion accounts for about 60-70% of dose (parent and metabolites). Biliary/fecal elimination is minimal.
Approximately 30% bound to plasma proteins, primarily albumin.
Acetaminophen: 10-25% bound, nonspecific binding to albumin. Hydrocodone: 25-50% bound, primarily to albumin and alpha-1-acid glycoprotein.
Vd is 0.6-0.9 L/kg, indicating distribution into total body water. Higher Vd may be observed in patients with heart failure.
Acetaminophen: 0.8-1.0 L/kg, indicating distribution into total body water; clinically relevant for loading dose calculations. Hydrocodone: 3.0-4.0 L/kg, suggesting extensive tissue distribution; higher Vd may require higher loading doses but has no clinical target.
Oral: 90-100% (sustained-release formulations). Sublingual: high but variable; generally effective due to extensive absorption.
Acetaminophen: oral bioavailability 85-95% (first-pass metabolism minimal). Hydrocodone: oral bioavailability about 25-45% due to first-pass hepatic metabolism; significant interindividual variability.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing dose to 10 mg twice daily due to potential accumulation of active metabolite.
GFR 10-50 m L/min: administer every 6 hours; GFR <10 m L/min: administer every 8 hours; avoid in severe impairment due to acetaminophen metabolite accumulation.
No dose adjustment in Child-Pugh A or B. For Child-Pugh C, reduce dose to 10 mg twice daily and monitor for hypotension.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: use with caution, avoid if possible, consider alternative therapy.
Safety and efficacy not established; no standard dosing recommendations.
Dosing based on hydrocodone component: 0.1-0.2 mg/kg/dose every 4-6 hours; maximum daily acetaminophen limit: 75 mg/kg/day; not recommended for children <2 years.
Start at 10 mg twice daily with gradual titration based on tolerance and renal function. Monitor for hypotension and dizziness.
Initiate at lowest effective dose, typically 1 tablet (2.5-5 mg hydrocodone) every 6 hours; monitor for respiratory depression and acetaminophen toxicity; avoid in frail elderly with hepatic impairment.
Do not use with phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen; neonatal opioid withdrawal syndrome; interaction with alcohol; risk of medication errors.
Hypotension and reflex tachycardia may occur,Caution in patients with volume depletion or hypotension,May cause headaches; tolerance may develop with prolonged use,Abrupt withdrawal may increase angina frequency
Hepatotoxicity from acetaminophen overdose; respiratory depression; increased intracranial pressure; CNS depression; elderly/debilitated patients; renal impairment; opioid-induced hyperalgesia; serotonin syndrome; interaction with CNS depressants; risk of adrenal insufficiency; severe hypotension; use in patients with gastrointestinal obstruction; convulsion risk; severe hepatic impairment; urinary retention; acute abdominal conditions; hypothyroidism; prostatic hypertrophy; adrenocortical insufficiency; pregnancy/lactation; pediatric use; geriatric use; renal impairment; hepatic impairment.
Concurrent use of PDE-5 inhibitors,Severe anemia,Closed-angle glaucoma,Hypersensitivity to isosorbide mononitrate or nitrates,Acute myocardial infarction with low filling pressures
Hypersensitivity to acetaminophen or hydrocodone; significant respiratory depression; acute or severe bronchial asthma; upper airway obstruction; known or suspected gastrointestinal obstruction; paralytic ileus; concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days; severe hepatic impairment (acetaminophen toxicity risk); acute alcoholism.
Alcohol may enhance hypotension risk. Avoid high-fat meals if extended-release formulation, as they may affect absorption. No other significant food interactions.
Avoid alcohol consumption during therapy; ethanol increases acetaminophen hepatotoxicity risk and enhances CNS depression. Grapefruit juice may inhibit CYP2D6 (minor effect) but no significant clinical interaction. No other specific food restrictions.
ISMO (isosorbide mononitrate) is categorized as FDA Pregnancy Category C. In animal studies, reduced fetal survival and growth retardation were observed at high doses. No adequate human studies exist. Use only if potential benefit justifies risk. First trimester: Theoretical risk of hemodynamic effects; avoid unless necessary. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; monitor fetal heart rate. Peripartum: May exacerbate uterine relaxation and postpartum hemorrhage if used near delivery.
First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital malformations (e.g., neural tube defects, cleft palate) with first trimester opioid use, but absolute risk is low. Second trimester: Low risk as above. Third trimester: Prolonged use of hydrocodone can cause neonatal opioid withdrawal syndrome (NOWS); acetaminophen is safe. Use only if benefit outweighs risk.
Excretion into human milk is unknown. Due to risk of infant methemoglobinemia and hypotension, caution is advised. M/P ratio: Not available. American Academy of Pediatrics considers nitrate derivatives compatible with breastfeeding, but monitor infant for cyanosis and lethargy.
Acetaminophen excretion in breast milk is low (M/P ratio ~0.9). Hydrocodone is excreted in small amounts (M/P ratio ~2.1). The relative infant dose is estimated to be 2.5-3.5% of maternal weight-adjusted dose for hydrocodone. Monitor infant for sedation and respiratory depression. Consider benefit to mother and potential neonatal opioid withdrawal if used chronically.
No specific dose adjustments for ISMO in pregnancy are established due to lack of pharmacokinetic studies. However, pregnancy-induced hemodynamic changes (increased plasma volume, cardiac output) may reduce efficacy; consider dose titration based on clinical response. Avoid doses >60 mg/day to minimize hypotensive risk. Use immediate-release formulations for flexible dosing if needed.
During pregnancy, increased plasma volume and enhanced hepatic clearance may reduce serum concentrations of both drugs. However, dosing adjustments are not routinely recommended due to risk of undertreatment. Use the lowest effective dose of hydrocodone for the shortest duration. For acetaminophen, maximum daily dose should not exceed 3000 mg to avoid hepatotoxicity.
ISMO (isosorbide mononitrate) is a nitrate used for angina prophylaxis, not for acute attacks. Tolerance develops with sustained use; maintain a 10-12 hour nitrate-free interval to prevent tolerance. Do not use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of profound hypotension. Contraindicated in severe anemia, increased intracranial pressure, or hypertrophic obstructive cardiomyopathy. Discontinue if blurred vision or dry mouth occurs.
Acetaminophen-hydrocodone is contraindicated in severe respiratory depression, acute or severe bronchial asthma, and known hypersensitivity. Monitor for respiratory depression, especially in elderly or debilitated patients. Avoid use with other acetaminophen-containing products to prevent hepatotoxicity. Hydrocodone is a prodrug metabolized by CYP2D6 to hydromorphone; CYP2D6 ultrarapid metabolizers may experience toxicity. Use with caution in patients with head injury, increased intracranial pressure, or severe hepatic impairment. Naloxone is the reversal agent for opioid effects; acetylcysteine for acetaminophen overdose.
Take as prescribed to prevent angina; do not use for acute attacks.,May cause headache, dizziness, or hypotension; rise slowly from sitting.,Avoid taking erectile dysfunction drugs (e.g., sildenafil, tadalafil) as severe blood pressure drop can occur.,Do not stop abruptly to avoid rebound angina.,Store in original container away from light and moisture.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness and respiratory depression.,Do not exceed 4000 mg of acetaminophen per day from all sources; check labels of other medications.,This medication may cause dizziness or drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Store securely out of reach of others, especially children, as misuse can cause overdose and death.,Do not stop abruptly; withdrawal may occur. Taper under medical supervision.,Contact emergency if you experience trouble breathing, extreme drowsiness, or signs of allergic reaction.,Report any history of substance abuse, as this medication has abuse potential.
"Bosentan, a dual endothelin receptor antagonist and an inducer of CYP3A4 and CYP2C9, reduces systemic exposure to vismodegib, a Hedgehog pathway inhibitor primarily metabolized by CYP3A4. This interaction leads to decreased serum concentrations of vismodegib, potentially diminishing its antitumor efficacy in patients with advanced basal cell carcinoma. Concomitant use may require vismodegib dose adjustment or alternative therapies to avoid therapeutic failure."
"Vismodegib inhibits CYP3A4, which is the primary enzyme responsible for metabolizing nilotinib. Concomitant administration may lead to increased nilotinib plasma concentrations, elevating the risk of QT interval prolongation, torsades de pointes, hepatotoxicity, and myelosuppression. Clinical vigilance is warranted due to the narrow therapeutic index of nilotinib."
"Vismodegib, a hedgehog pathway inhibitor, is a moderate inhibitor of CYP2C9, the primary enzyme responsible for metabolizing tolbutamide. Concomitant use can significantly decrease tolbutamide clearance, leading to elevated plasma concentrations and prolonged hypoglycemic effects. This increases the risk of severe hypoglycemia, especially in diabetic patients, and may require dose adjustment of tolbutamide."
"Hydrocodone, an opioid agonist, and scopolamine, an anticholinergic agent, both exhibit central nervous system (CNS) depressant effects. When co-administered, their combined activity can lead to additive CNS depression, resulting in enhanced sedation, respiratory depression, and cognitive impairment. This interaction may also increase the risk of constipation and urinary retention due to additive anticholinergic effects from both drugs."
"Pargyline, a monoamine oxidase inhibitor (MAOI), irreversibly inhibits the metabolism of amines, leading to increased intraneuronal stores of norepinephrine. Hydrocodone, a semisynthetic opioid, can release these stored catecholamines, potentially causing a hypertensive crisis, serotonin syndrome, or CNS excitation. Coadministration may also result in excessive sedation and respiratory depression due to additive CNS depressant effects, requiring immediate clinical attention."
"Hydrocodone, an opioid agonist, and oxprenolol, a non-selective beta-adrenoceptor antagonist, are both central nervous system (CNS) depressants. Their combined use can lead to additive CNS depression, resulting in excessive sedation, respiratory depression, hypotension, and bradycardia. This interaction is particularly dangerous in patients with compromised cardiac or respiratory function, potentially leading to coma or death."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISMO vs ACETAMINOPHEN AND HYDROCODONE BITARTRATE, answered by our medical review team.
ISMO is a Nitrate Vasodilator that works by Isosorbide mononitrate is a nitrate that dilates coronary arteries and peripheral veins. It acts by releasing nitric oxide, which activates guanylate cyclase, increasing c GMP levels, leading to smooth muscle relaxation and vasodilation.. ACETAMINOPHEN AND HYDROCODONE BITARTRATE is a Opioid Agonist that works by Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISMO and ACETAMINOPHEN AND HYDROCODONE BITARTRATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISMO is: 20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to minimize nitrate tolerance.. The standard adult dose of ACETAMINOPHEN AND HYDROCODONE BITARTRATE is: 1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISMO and ACETAMINOPHEN AND HYDROCODONE BITARTRATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISMO is classified as Category C. ISMO (isosorbide mononitrate) is categorized as FDA Pregnancy Category C. In animal studies, reduced fetal survival and growth retardation were observed at high doses. No adequate . ACETAMINOPHEN AND HYDROCODONE BITARTRATE is classified as Category D/X. First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.